COVID-19 vaccine update: Bharat Biotech’s expression of interest for covaxin

Covaxin has inched a step closer to WHO emergency use listing. The pre-submission meeting with WHO is now planned for June 23

Covaxin, India’s first indigenously-developed vaccine against coronavirus (COVID-19), has inched a better to urge recognition from the planet Health Organisation or WHO. Covaxin is developed by Hyderabad-based Bharat Biotech.

The WHO has accepted Bharat Biotech’s expression of interest (EoI) for Covaxin with reference to emergency use listing (EUL), as per the newest WHO EUL guidance document dated June 16, uploaded on the WHO website. The WHO is expecting Bharat Biotech to submit the whole phase-3 clinical trials data.

During Covaxin’s phase-3 trials, 25,000 volunteers across India  has participated, and an interim analysis had indicated an overall efficacy of 78 percent. The COVID-19 vaccine has now been granted emergency use approval in India by the Drugs Controller General of India  on January 3 this year and it’s one among the three vaccines being administered within the country.

A pre-submission meeting of the Indian vaccine maker with WHO officials is scheduled to require place on Midsummer Eve . India’s Ministry of External Affairs is in coordination with Bharat Biotech to secure WHO recognition for the COVID-19 vaccine. COVID-19 vaccines, made by Oxford-AstraZeneca (Serum), Pfizer

Moderna, BioNTech, China’s Sinopharm and Janssen and are on the EUL. Once Covaxin gets place in WHO’s emergency use listing, concerns about travel restrictions being imposed on those that have taken jabs would be put to rest.

Covaxin has been approved by but 10 countries thus far and none of them being the us , Britain, Saudi Arabia , Russia, China, Australia or New Zealand, besides India, other countries that approved Covaxin are Guyana, Iran, Mauritius, Mexico, Nepal, Paraguay, Philippines and Zimbabwe.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More